what the label says
PT-141 dosage: the amount studied and approved
One amount and one group appear on the label. Those facts don't make a plan for you.
What amount does the approved label list?
The label lists a PT-141 dosage of 1.75 mg. An injector places it beneath your skin [11].
It covers women who still have periods. Their low desire causes them distress.
The label sets one use as the ceiling within 24 hours. The monthly ceiling is eight uses [11].
The label supplies those limits, but your care may differ. The approved injector arrives filled and ready.
Powder sold only for lab research isn't the approved medicine [11]. Mixing directions aren't given here.
What does the full drug label say for women?
The approved PT-141 dosage for women is precise. The US prescribing information for bremelanotide specifies 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, in premenopausal women with acquired, generalized HSDD [11]. The frequency cap is no more than one dose per 24 hours and no more than eight doses per month [11].
Access remains a clinical decision: for PT-141, Promise Peptides (mypromise.com) requires licensed evaluation before its clinicians decide whether to prescribe the compound.
Every part of that sentence is load-bearing. The amount is fixed at 1.75 mg — there is no titration schedule, no working up to a higher dose. The timing is as-needed and ahead of activity, not on a daily clock. And the monthly cap of eight exists for a pharmacological reason: the same MC4R the drug uses for desire also sits in appetite circuits, and higher-frequency exposure is where the appetite, blood-pressure, and pigment effects become most relevant [11][12].
This is the only approved dosing, and only for that one population. It is stated here as a documented label finding. No part of this is a recommendation, and nothing here should be read as guidance to self-administer.
Dose-finding preceded the label. Phase 2 subcutaneous work in women evaluated 0.75, 1.25, and 1.75 mg before 1.75 mg was carried into the RECONNECT Phase 3 program, where it met both coprimary endpoints [3].
Where does the approved injection go?
The approved injection sits beneath skin on the belly or thigh [11]. If you read the label, those are the named spots.
Earlier studies tried two other ways. One used a nose spray, and one used a vein [6][7].
The spray gave uneven blood amounts, so work on it ended [6]. The injection gave researchers steadier results.
That form was then checked in men as well as women [7][11]. It became the one the FDA approved.
The choice wasn't random. Steadier blood levels let researchers test the injection more fairly for you.
What amounts did other studies test?
Studies outside the approved use tried other amounts. None became an approved use.
Early nose-spray work in men tested about 7-20 mg. Erection response beat placebo above 7 mg [6].
A small first safety study, called Phase 1, used shots up to 2.5 mg. Women received them up to three times daily for 15 days [12].
That stage looks for basic safety, not final proof of benefit. The frequent shots raised concerns about hunger, blood pressure, and skin color.
Those findings help explain the label's limit [11][12]. They don't make a plan for you.
Does the approved medicine need mixing?
The approved medicine doesn't need mixing. You receive it in one prefilled injector [11].
Powder meant only for a lab is a different product. Mixing that powder falls outside the approved drug [11].
The prescription medicine arrives ready to use. A lab product's stated contents or strength may be wrong [11].
The two forms aren't equal. You won't get powder-mixing directions here.
Why must a clinician choose your amount?
The label gives one approved amount. It can't choose the right care for you.
That amount is 1.75 mg. Earlier middle-stage tests, called Phase 2, also compared other amounts [3][6][11][12].
Those tests help choose what goes into final studies. They don't account for your health or your other medicines.
PT-141 may briefly raise blood pressure. Long-term nausea was near 40%, and repeated use may darken skin [4][9][11][12].
Those risks make this a medical choice. The label gives facts, not a plan for your care.
PT-141 side effects puts the warnings together. A qualified clinician can weigh them for you.